Anlotinib and Irinotecan for Ewing Sarcoma
Keywords
Coimriú
Cur síos
After standard multimodal therapy, the prognosis of relapsed and metastatic Ewing Sarcoma is dismal and unchanged over the last decades.Thus, the investigators explored the activity of anlotinib combined with irinotecan in patients with relapsed and metastatic Ewing Sarcoma after the failure of first-line chemotherapy with doxorubicin, vincristine, cyclophosphamide, ifosphamide and etoposide.
Dátaí
| Fíoraithe Deireanach: | 01/31/2019 |
| Cuireadh isteach den chéad uair: | 01/23/2018 |
| Clárú Measta Curtha isteach: | 01/28/2018 |
| Arna chur suas ar dtús: | 01/30/2018 |
| Nuashonrú Deireanach Curtha isteach: | 02/12/2019 |
| Nuashonrú Deireanach Postáilte: | 02/14/2019 |
| Dáta Tosaigh an Staidéir Iarbhír: | 01/21/2018 |
| Dáta Críochnaithe Bunscoile Measta: | 01/31/2020 |
| Dáta Críochnaithe an Staid Mheasta: | 11/30/2020 |
Coinníoll nó galar
Idirghabháil / cóireáil
Drug: Anlotinib
Drug: Irinotecan
Céim
Grúpaí Láimhe
| Lámh | Idirghabháil / cóireáil |
|---|---|
| Experimental: Anlotinib and Irinotecan(phase 1b) Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15mg/m^2/d over 60 minutes on days 1-5 and 8-12 q3w. Vincristine 1.4mg/m^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. | |
| Experimental: Anlotinib and Irinotecan(phase 2) Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15 mg/m^2/d IV over 60 minutes on days 1-5 and 8-12 q3w. The final dose of anlotinib and irinotecan depends on the result from previous phase Ib study. Vincristine 1.4mg/m^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. |
Critéir Incháilitheachta
| Aois Incháilithe le haghaidh Staidéir | 5 Years Chun 5 Years |
| Gnéas Incháilithe le haghaidh Staidéir | All |
| Glacann Oibrithe Deonacha Sláintiúla | Sea |
| Critéir | Inclusion Criteria: - Histologically confirmed Ewing sarcoma. - Evidence of Ewing sarcoma translocation by fluorescence in situ hybridization (FISH) or real-time polymerase chain reaction (RT-PCT). - Recurrent or refractory tumors with no known curative treatment options according to the judgment of the investigator. - Prior treatment consisted of standard Ewing Sarcoma chemotherapy agents including doxorubicin, vincristine, cyclophosphamide, ifosfamide and etoposide; metastatic relapsed and unresectable progressive disease (PD); - Life expectancy of ≥ 3 months. - Eastern Cooperative Oncology Group performance status 0-1 - Measurable disease on CT or MRI by RECIST 1.1. - Adequate organ function. - Time elapsed from previous therapy must be ≥ 3 weeks for systemic therapy, ≥ 2 weeks for radiation therapy or major surgery. - Patients who have undergone autologous hematopoietic stem cell transplantation are eligible once they have recovered from all toxicities from therapy. - Patients who have received allogeneic hematopoietic stem cell transplantation will be eligible 6 months after the procedure provided there is no evidence of active graft-versus-host disease and immunosuppressive treatment has been discontinued for at least 30 days. - Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of central nervous system metastatic disease, have been off glucocorticoids for at least 4 weeks, have no overt evidence of neurological deficit and are ≥ 6 weeks from completion of brain irradiation. - Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication. Exclusion Criteria: - Clinically significant unrelated illness which would, in the judgment of the treating physician, compromise the patient's ability to tolerate the investigational agent or be likely to interfere with the study procedures or results. - Prior treatment consisted of anlotinib, any other antiangiogenic TKIs, or irinotecan. - Patients with baseline corrected QT interval(QTc) > 480 msec. - Known hypersensitivity reaction to anlotinib or any of its components, and irinotecan or any of its components. - Concomitant use of any other investigational or anticancer agent(s). - Pregnant patients or patients who are breast feeding. Subjects capable of pregnancy (post menarche and not post-menopausal, defined as over 12 months since final menstrual period) must have a negative pregnancy test within 7 days prior to first dose. - Inability to swallow capsules or water. - Other clinically significant malignant disease diagnosed within the previous 5 years, excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer. - Known persistent (> 4 weeks) ≥ Grade 2 neutropenia, ≥ Grade 2 thrombocytopenia or > Grade 3 anemia from prior cancer therapy. - Other kinds of malignant tumors at the same time. |
Toradh
Bearta Toraidh Príomhúla
1. Maximum tolerated dose (MTD) (phase 1b) [12 months]
2. Object response rate(ORR) at 12 weeks (phase 2) [12 months]
Bearta Torthaí Tánaisteacha
1. Progression-free survival(PFS) [2 years]
2. Overall survival(OS) [2 years]
3. Adverse Effect [2 years]
4. Quality of Life (QoL) [2 years]
5. Pain management [2 years]
